Ed Kaye joined Sarepta Therapeutics in June 2011 as Chief Medical Officer. Previously he served as Group Vice President for Clinical Development and Therapeutic Head for Lysosomal Storage Disorders and Neurodegenerative Diseases at Genzyme since 2007. Ed held additional leadership roles in Clinical Development and Medical Affairs over 10 years at Genzyme and developed specific experience with pediatric neuromuscular conditions. He played a leadership role in gaining Myozyme’s approval for Pompe Disease and oversaw collaborations in this field, including the development of ataluren for Duchenne Muscular Dystrophy (DMD). Prior to joining Genzyme, Ed was Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at University of Pennsylvania School of Medicine. Before this, he was Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher’s Hospital for Children in Philadelphia. Ed is a member of several scientific advisory boards, including the CureDuchenne, CureCMD (Congenital Muscular Dystrophy) and Spinal Muscular Atrophy Foundation advisory boards. He received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University.
Senior Vice President, Chief Medical Officer
|Sep 19, 2016||Business Wire - CureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy|
|May 6, 2016||Business Wire - Annual BLINGO Raises $200,000 for CureDuchenne|
|Mar 31, 2015||Fierce Biotech - UPDATED: Sarepta's embattled CEO steps down as DMD drug heads to the FDA|